- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
DEA: These steroids should be exempt
DEA is designating six pharmaceutical products as exempt anabolic steroids under the Controlled Substances Act. The reason is that these six products are similar to other preparations that have already been exempted.
DEA: These steroids should be exempt
DEA is designating six pharmaceutical products as exempt anabolic steroids under the Controlled Substances Act. The reason is that these six products are similar to other preparations that have already been exempted. The six products include various dosages of esterified estrogens and methyltestosterone from Interpharm Inc., Lannett Co., and ANDAPharm LLC. DEA published this interim rule in the Sept. 1 Federal Register. Stating that the rule is effective as of Sept. 1, the FDA nevertheless said it seeks comments, which should reach the agency by Oct. 31.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Pharmaceutical Compounding, Storage of Faricimab Preserves Stability, Binding Properties
November 28th 2023Maintaining the structure and function of antibody biologics like faricimab is critical for their administration via intravitreal injection (IVI), a common treatment approach for retinal diseases.
